Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

http://scihub22266oqcxt.onion/ 33283842!ä!33283842 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Ann+Acad+Med+Singap 2020 ; 49 (10): 789-800 Nephropedia Template TP {{tp|p=33283842|t=2020. The Role of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis |pdf=|usr=}}{{33283842}} gab.com Text The Role of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis JO: Ann Acad Med Singap http://www.kidney.de/pget.php?&tw=1&pmid=33283842 #FOAvip OBJECTIVE: A systematic review and meta-analysis was carried out to examine the role of hydroxychloroquine (HCQ) in the treatment of COVID-19. METHODS: We performed a systematic search in PubMed, Scopus, Embase, CochraneLibrary, Web of Science, Google Scholar, and medRxiv pre-print databases using available MeSH terms for COVID-19 and hydroxychloroquine. Data from all studies that focused on the effectiveness of HCQ with or without the addition of azithromycin (AZM) in confirmed COVID-19 patients, which were published up to 12 September 2020, were collated for analysis using CMA v.2.2.064. RESULTS: Our systematic review retrieved 41 studies. Among these, 37 studies including 45,913 participants fulfilled the criteria for subsequent meta-analysis. The data showed no significant difference in treatment efficacy between the HCQ and control groups (RR: 1.02, 95% CI, 0.81-1.27). Combination of HCQ with AZM also did not lead to improved treatment outcomes (RR: 1.26, 95% CI, 0.91-1.74). Furthermore, the mortality difference was not significant, neither in HCQ treatment group (RR: 0.86, 95% CI, 0.71-1.03) nor in HCQ plus AZM treatment group (RR: 1.28, 95% CI, 0.76-2.14) in comparison to controls. Meta-regression analysis showed that age was the factor that significantly affected mortality (P<0.00001). CONCLUSION: The meta-analysis found that there was no clinical benefit of using either HCQ by itself or in combination with AZM for the treatment of COVID-19 patients. Hence, it may be prudent for clinicians and researchers to focus on other therapeutic options that may show greater promise in this disease. Twit Text FOAVip The Role of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis ????Ann Acad Med Singap http://www.kidney.de/pget.php?&tw=1&pmid=33283842 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33283842 #FOAvip English Wikipedia <ref>{{Cite pmid|33283842}}</ref> The Role of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis #MMPMID33283842 Shamshirian A; Hessami A; Heydari K; Navaei RA; Ebrahimzadeh MA; Yip GW; Ghasemian R; Sedaghat M; Baradaran H; Yazdi SM; Aboufazeli E; Jafarpour H; Dadgostar E; Tirandazi B; Sadeghnezhad R; Karimifar K; Eftekhari A; Shamshirian D Ann Acad Med Singap 2020[Oct]; 49 (10): 789-800 PMID33283842show ga OBJECTIVE: A systematic review and meta-analysis was carried out to examine the role of hydroxychloroquine (HCQ) in the treatment of COVID-19. METHODS: We performed a systematic search in PubMed, Scopus, Embase, CochraneLibrary, Web of Science, Google Scholar, and medRxiv pre-print databases using available MeSH terms for COVID-19 and hydroxychloroquine. Data from all studies that focused on the effectiveness of HCQ with or without the addition of azithromycin (AZM) in confirmed COVID-19 patients, which were published up to 12 September 2020, were collated for analysis using CMA v.2.2.064. RESULTS: Our systematic review retrieved 41 studies. Among these, 37 studies including 45,913 participants fulfilled the criteria for subsequent meta-analysis. The data showed no significant difference in treatment efficacy between the HCQ and control groups (RR: 1.02, 95% CI, 0.81-1.27). Combination of HCQ with AZM also did not lead to improved treatment outcomes (RR: 1.26, 95% CI, 0.91-1.74). Furthermore, the mortality difference was not significant, neither in HCQ treatment group (RR: 0.86, 95% CI, 0.71-1.03) nor in HCQ plus AZM treatment group (RR: 1.28, 95% CI, 0.76-2.14) in comparison to controls. Meta-regression analysis showed that age was the factor that significantly affected mortality (P<0.00001). CONCLUSION: The meta-analysis found that there was no clinical benefit of using either HCQ by itself or in combination with AZM for the treatment of COVID-19 patients. Hence, it may be prudent for clinicians and researchers to focus on other therapeutic options that may show greater promise in this disease. |*COVID-19 Drug Treatment[MESH] |Antiviral Agents/*therapeutic use[MESH] |Azithromycin/therapeutic use[MESH] |COVID-19/prevention & control[MESH] |Drug Therapy, Combination[MESH] |Humans[MESH] |Hydroxychloroquine/*therapeutic use[MESH] |Intubation, Intratracheal/statistics & numerical data[MESH] |Mortality[MESH] |Severity of Illness Index[MESH]The Role of Hydroxychloroquine in COVID-19: A Systematic Review and M(epmc).pdf DeepDyve Pubget Overpricing